Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma

Next Previous
X
Search
Trial Profile

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelarabine (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Mercaptopurine; Mesna; Methotrexate; Pegaspargase; Prednisone; Venetoclax; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Dec 2024 The protocol was modified to incorporate PegAsp during consolidation and then venetoclax; the regimen was further amended to dose venetoclax based on the phenotype and response status to reduce risk of myelosuppression as per results published in the Leukemia
    • 01 Dec 2024 Results presenting long-term follow-up from the study including the patients treated with the addition of venetoclax, following the amendment published in the Leukemia
    • 27 Aug 2024 Planned End Date changed from 31 Oct 2024 to 31 Oct 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top